CP5484, a novel quaternary carbapenem with potent anti-MRSA activity and reduced toxicity

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 19, 2007, Pages 6379-6387

  Maruyama, Takahisa ^a   Yamamoto, Yasuo ^a   Kano, Yuko ^a   Kurazono, Mizuyo ^a   Matsuhisa, Eiji ^a   Takata, Hiromi ^a   Takata, Toshihiko ^a   Atsumi, Kunio ^a   Iwamatsu, Katsuyoshi ^a   Shitara, Eiki ^a  

^a MEIJI SEIKA KAISHA LTD   (Japan)

Author keywords

Anti MRSA activity; Carpabapenem; CP5484; MRSA; Toxicity

Indexed keywords

2 [6 (3 AMINO 2 HYDROXY)PROPYL 7 METHYLTHIOIMIDAZO[5,1 B]THIAZOLIUM 2 YL] 6 (1 HYDROXYETHYL) 1 METHYL 1 CARBAPEN 2 EM 3 CARBOXYLATE; CARBAPENEM DERIVATIVE; CILASTATIN; CP 5484; IMIDAZO[5,1 B]THIAZOL 2 YL DERIVATIVE; IMIPENEM; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; IMIDAZOLES; KINETICS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUS;

EID: 34547685940     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.06.057     Document Type: Article

References (16)

1. Jovens M.P. Br. Med. J. 1 (1961) 124
2. Murray B.E. Am. J. Med. 102 (1997) 284
3. Moellering R.C. Clin. Inf. Dis. 26 (1998) 1196
4. Woodford N. Clin. Microbiol. Infect. 11 (2005) 2
5. Mangili A., Bica I., Snydman D.R., and Hamer D.H.H. Infect. Dis. 40 (2005) 1058
6. Tsushima M., Iwamatsu K., Tamura A., and Shibahara S. Bioorg. Med. Chem. 6 (1998) 1009
7. Spronger D.M., Luh B., and Bronson J.J. Bioorg. Med. Chem. Lett. 11 (2001) 797
8. Ratcliffe R.W., Wilkening R.R., Wildonger K.J., Waddell S.T., Santorelli G.M., Parker Jr. D.L., Morgan J.D., Blizzard T.A., Hammond M.L., Heck J.V., Huber J., Kohler J., Dorso K.L., St. Rose E., Sundelhof J.G., May W.J., and Hammond G.G. Bioorg. Med. Chem. Lett. 9 (1999) 679
9. Ohtake N., Imamura H., Jona H., Kiyonaga H., Shimizu A., Moriya M., Sato H., Nakano M., Ushijima R., and Nakagawa S. Bioorg. Med. Chem. 5 (1997) 1089
10. Shinagawa H., Yamaga H., Houchigai H., Sumita Y., and Sunagawa M. Bioorg. Med. Chem. 6 (1998) 601
11. Shitara, E.; Sasaki, T.; Yamamoto, Y.; Kano, Y.; Maruyama, T.; Kitagawa, H.; Toyooka, Y.; Aihara, K.; Atsumi, K.; Yamada, K.; Tohyama, K.; Matsuhisa, E.; Hiranuma, T.; Iwamatsu, K. Abstract of Papers, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada; American Society for Microbiology: Washington, DC, 2000; Abstract F1236.
12. Hecker S.J., Glinka T.W., Cho A., Zhang Z.J., Price M.E., Chamberland S., Griffith D., and Lee V.J. J. Antibiot. 53 (2000) 1045
13. Imamura H., Ohtake N., Shimazu A., Jona H., Sato H., Nagano R., Ushijima R., Yamada K., Hashizume T., and Morishima H. Bioorg. Med. Chem. Lett. 10 (2000) 109
14. Imamura H., Ohtake N., Shimazu A., Sato H., Sugimoto Y., Sakuraba S., Kiyonaga H., Suzuki-Sato C., Nakano M., Nagano R., Yamada K., Hashizume T., and Morishima H. Bioorg. Med. Chem. Lett. 10 (2000) 115
15. Sato H., Sakoh H., Hashihayata T., Imamura H., Ohtake N., Shimizu A., Sugimoto Y., Sakuraba S., Bamba-Nagano R., Yamada K., Hashizume T., and Morishima H. Bioorg. Med. Chem. 10 (2002) 1595
16. Pharmacokinetic parameter of imipenem is described in Chemotherapy. 1985, 33, 14.